Pharmaceutical Industry Articles & Expert Analysis | Pharma’s Almanac

Articles

Pharma's Almanac offers a combination of internal editorial thought leadership and contributed articles spanning a diversity of topics spanning the pharma/biopharma, life science industrials, R&D, and outsourcing landscape to keep readers current on trending topics, developments, and opinions.

Nice Insight is the market research division of That's Nice LLC, the leading marketing agency serving life sciences.

Explore

About Us Nice Insight That's Nice

Reach Our Team

Contact Us Advertise LinkedIn

My Account

Subscribe for the newsletter

© 2026 PHARMA'S ALMANAC. All rights reserved.

Privacy Policy Terms And Conditions

Rebuilding the Psychiatric Drug Discovery Pipeline

Psych R&D

Rebuilding the Psychiatric Drug Discovery Pipeline

David Alvaro, Ph.D.

Pharma's Almanac

PAO-05-26-PA-14May 13, 2026

The Intersection of Pharmaceutical Tariffs, Outsourcing, and Investment: Balance is Key

Tariffs

The Intersection of Pharmaceutical Tariffs, Outsourcing, and Investment: Balance is Key

Cynthia A. Challener, Ph.D.

Pharma's Almanac

PAO-04-26-PA-15Apr 15, 2026

Where Capital Meets CMC: The Emerging Role of CDMOs in Investor Risk Assessment

CMC and Investment

Where Capital Meets CMC: The Emerging Role of CDMOs in Investor Risk Assessment

David Alvaro, Ph.D.; Daniel Smith, Ph.D.

Pharma's Almanac

PAO-01-26-NI-15Jan 15, 2026

When Fewer Shots on Goal Change the Science: How Capital Discipline Is Reshaping R&D Strategy

R&D Funding

When Fewer Shots on Goal Change the Science: How Capital Discipline Is Reshaping R&D Strategy

David Alvaro, Ph.D.; Daniel Smith, Ph.D.

Pharma's Almanac

PAO-01-26-NI-07Jan 9, 2026

Risk-Sharing Rewritten: How Biopharma Partnerships Are Redesigning Incentives Beyond the Deal

Risk Sharing

Risk-Sharing Rewritten: How Biopharma Partnerships Are Redesigning Incentives Beyond the Deal

David Alvaro, Ph.D.

Pharma's Almanac

PAO-01-26-NI-05Jan 9, 2026

Structured Deals on the Rise: Milestones, Options, and Risk-Sharing in Biopharma Licensing

Partnerships

Structured Deals on the Rise: Milestones, Options, and Risk-Sharing in Biopharma Licensing

David Alvaro, Ph.D.

Pharma's Almanac

PAO-01-26-NI-04Jan 8, 2026

The Economics of Big Science — and Why It Matters for Drug Development

Big Science

The Economics of Big Science — and Why It Matters for Drug Development

David Alvaro, Ph.D.

Pharma's Almanac

PAO-01-26-NI-06Jan 6, 2026

Selective Capital, Stronger Science: The Emerging Biotech Funding Model

Biotech Funding

Selective Capital, Stronger Science: The Emerging Biotech Funding Model

David Alvaro, Ph.D.

Pharma's Almanac

PAO-12-25-NI-04Jan 6, 2026

Fewer, Bigger, Smarter: How Pharma M&A Evolved in 2025 — and What Comes Next

M&A

Fewer, Bigger, Smarter: How Pharma M&A Evolved in 2025 — and What Comes Next

David Alvaro, Ph.D.

Pharma's Almanac

PAO-12-25-NI-07Dec 17, 2025

Beyond Borders: A Disciplined Approach to Successful Global Expansion

Global Growth

Beyond Borders: A Disciplined Approach to Successful Global Expansion

Eric B. Lev

Ampersand Capital Partners

PAO-08-25-CL-11Nov 4, 2025

The Strategic Case for Investing in Pediatric Oncology, Beyond Altruism

Pediatric Oncology

The Strategic Case for Investing in Pediatric Oncology, Beyond Altruism

Emilee Kudla

Pharma's Almanac

PAO-08-25-NI-04Aug 5, 2025

The "Therapeutic Winter" and Why Urgent Innovation in Pediatric Oncology Is Being Left Behind

Pediatric Oncology

The "Therapeutic Winter" and Why Urgent Innovation in Pediatric Oncology Is Being Left Behind

Emilee Kudla

Pharma's Almanac

PAO-08-25-NI-03Aug 5, 2025

Cutting Public R&D Would Slash U.S. GDP, Innovation, and Industry Growth, New Report Warns

R&D Funding

Cutting Public R&D Would Slash U.S. GDP, Innovation, and Industry Growth, New Report Warns

David Alvaro, Ph.D.

Pharma's Almanac

PAO-04-25-NI-15Apr 30, 2025

A Reversal Isn’t a Rescue: Women’s Health Still Needs Defending

WHI

A Reversal Isn’t a Rescue: Women’s Health Still Needs Defending

David Alvaro, Ph.D.

Pharma's Almanac

PAO-04-25-NI-14Apr 25, 2025

The White House’s War on the NIH and the Disasters Ahead

NIH

The White House’s War on the NIH and the Disasters Ahead

David Alvaro, Ph.D.

Pharma's Almanac

PAO-03-25-NI-05Mar 24, 2025

Employees Who Think Like Stakeholders: The Power of Transparency and Empowerment

Financial Literacy

Employees Who Think Like Stakeholders: The Power of Transparency and Empowerment

Emilee Kudla

Pharma's Almanac

PAO-03-25-NI-01Mar 14, 2025

Conversations with Carleone: Leadership Wisdom Worth Sharing

Leadership Wisdom

Conversations with Carleone: Leadership Wisdom Worth Sharing

Emilee Kudla; Joseph Carleone

Pharma's Almanac

PAO-03-25-NI-02Mar 14, 2025

Science Under Siege: The Devastating Consequences of Public Health and Research Cuts

Federal Job Cuts

Science Under Siege: The Devastating Consequences of Public Health and Research Cuts

David Alvaro, Ph.D.

Pharma's Almanac

PAO-02-25-NI-04Feb 19, 2025

Revolutionizing xRNA Production: The Economic Case for Continuous Manufacturing

xRNA

Revolutionizing xRNA Production: The Economic Case for Continuous Manufacturing

Aaron B. Cowley, Ph.D.

Recipharm Advanced Bio

PAO-02-25-CL-11Feb 13, 2025

NIH Funding Cuts Put Innovation, Health Equity, and Lives at Risk

NIH Funding

NIH Funding Cuts Put Innovation, Health Equity, and Lives at Risk

David Alvaro, Ph.D.

Pharma's Almanac

PAO-02-25-NI-03Feb 10, 2025